<DOC>
	<DOCNO>NCT00980031</DOCNO>
	<brief_summary>The goal project investigate effect addition aldosterone blockade eplerenone progression diastolic dysfunction patient control essential hypertension .</brief_summary>
	<brief_title>Aldosterone Blockade Prevent Myocardial Remodeling In Patients With Controlled Essential Hypertension</brief_title>
	<detailed_description>The purpose project determine eplerenone , aldosterone blocker , prevents remodelling heart patient control essential hypertension , define blood pressure equal le 130/80 diabetic equal less 140/90 non-diabetics . This study investigate addition 25 milligram eplerenone daily subject 's hypertension medication regimen prevent progression development diastolic dysfunction . Echocardiography use measure change heart structure subject receive eplerenone versus subject receive placebo ( drug may resemble study drug contains active ingredient ) . Approximately 30 subject take part study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<criteria>Treated controlled hypertension Less 140/90 nondiabetics Less 130/80 diabetic currently receive aldosterone blocker clinical evidence congestive heart failure prior myocardial infarction renal dysfunction creatinine clearance le 40ml/min serum potassium &gt; 5.5meq/L initiation concomitant use medication inhibits CYP3A4 enzyme ( ketoconazole , itraconazole , nefazodone , troleandomycin , clarithromycin , ritonavir , nelfinavir )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Aldosterone Blockade</keyword>
	<keyword>Aldosterone Receptor Blockers</keyword>
	<keyword>cardiac chamber size</keyword>
	<keyword>wall thickness</keyword>
	<keyword>leave ventricular ejection fraction</keyword>
	<keyword>leave atrial volume</keyword>
	<keyword>diastolic function</keyword>
</DOC>